Solus Advanced Materials' bio biz sets off as Solus Biotech
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Solus Advanced Materials, formerly known as Doosan Solus, said Friday it had split off its bio division as a wholly owned subsidiary Solus Biotech to target the global mRNA vaccine market.
The new bio subsidiary will be led by Seo Kwang-byeok, the current CEO of Solus Advanced Materials, and target an annual revenue of 120 billion won ($100 million) by 2025.
Solus Biotech supplies organic compounds to global manufacturers of cosmetic, food and pharmaceutical products. The firm commands 95 percent of the domestic ceramide market, a type of fat commonly used for skin care products to retain moisture.
Based on its expertise in organic compounds, Solus Biotech aims to develop a nano material that helps the delivery of an mRNA vaccine inside a human body.
By Kim Byung-wook(kbw@heraldcorp.com)
Copyright © 코리아헤럴드. 무단전재 및 재배포 금지.